Erasca (ERAS) Total Liabilities (2020 - 2026)
Erasca's (ERAS) quarterly Total Liabilities came in at $67.7 million in Q1 2026, down 5.63% YoY from $71.7 million in Q1 2025, and down 4.62% on a QoQ basis from $71.0 million in Q4 2025.
Erasca (ERAS) Total Liabilities (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Total Liabilities data on file, last reported at $67.7 million in Q1 2026.
- Quarterly Total Liabilities fell 5.63% year-over-year to $67.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.7 million (down 5.63% YoY) and the FY2025 annual result came in at $71.0 million, down 10.18% from the prior year.
- Total Liabilities eased to $67.7 million in Q1 2026, from $71.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $103.1 million in Q4 2022 to a low of $49.8 million in Q2 2022.
- A 5-year average of $74.9 million and a median of $78.0 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 154.09% — and 2023, when it dropped 23.72%.
- Tracing ERAS's Total Liabilities over 5 years: stood at $103.1 million in 2022, then retreated by 23.72% to $78.6 million in 2023, then increased by 0.53% to $79.0 million in 2024, then slipped by 10.18% to $71.0 million in 2025, then fell by 4.62% to $67.7 million in 2026.
- The last three Total Liabilities figures came in at $67.7 million (Q1 2026), $71.0 million (Q4 2025), and $72.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 73.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.19 Mn |
| Mar 31, 2026 | 67.71 Mn |
| Dec 31, 2025 | 70.98 Mn |
| Sep 30, 2025 | 72.52 Mn |
| Jun 30, 2025 | 73.13 Mn |
| Mar 31, 2025 | 71.74 Mn |
| Dec 31, 2024 | 79.03 Mn |
| Sep 30, 2024 | 78.85 Mn |
| Jun 30, 2024 | 74.66 Mn |
| Mar 31, 2024 | 81.61 Mn |
| Dec 31, 2023 | 78.61 Mn |
| Sep 30, 2023 | 80.43 Mn |
| Jun 30, 2023 | 77.96 Mn |
| Mar 31, 2023 | 81.09 Mn |
| Dec 31, 2022 | 103.06 Mn |
| Sep 30, 2022 | 81.11 Mn |
| Jun 30, 2022 | 49.76 Mn |
| Mar 31, 2022 | 50.81 Mn |
| Dec 31, 2021 | 44.89 Mn |
| Sep 30, 2021 | 38.96 Mn |